BRAF- or KRAS-driven colorectal cancer and BRAF-driven melanoma exhibit increased glycolysis [58,68], and inhibition of BRAFV600E suppressed the levels of glycolysis in BRAF-driven melanoma [69]. This evidence concerns the gene BRAF and colorectal cancer.